Author(s)

Yuqing Huang, Zaiyou Tan, Lin Luo, Hui Yang, Chunmei Tong, Wenfei Chen, Tingyu Huang, Ruiling Liu

School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou, China..

Objective: To determine the transformation between two known crystal forms of the title compound (C₁₈H₂₃NO₃, Mr = 301.37). Methods: To recrystallize or heat the crystals and determine the crystal form by testing the melting points. Results: Both the two known crystal forms of the title compound can be changed by dissolving into different organic solvents such as acetone and ethyl acetate. Crystal form I was not influenced by heating while crystal form II can be transformed to crystal form I through melting method. Conclusion: Organic solvents have significant influences on the two crystal forms of title compound. Crystal form I shows a better thermal stability than crystal form II.

SU2162; Polymorphism; Crystal Form; Melting Method; Solvent Method

Y. Huang, Z. Tan, L. Luo, H. Yang, C. Tong, W. Chen, T. Huang and R. Liu, "The Polymorphism and Transformation of (3aRS, 4RS, 7RS, 7aSR)-2-(Tricyclo[3.3.1.13,7]decan-1-yl)-4,5,6,7-tetrahydro-4,7-eposyisoindoline-1,3-dione (SU2162)—A Novel Anticancer Compound," Journal of Crystallization Process and Technology, Vol. 4 No. 1, 2014, pp. 27-30. doi: 10.4236/jcpt.2014.41004.